Oesophageal cancer-specific mortality risk and public health insurance: Prospective cohort study from China

doi:10.4251/wjgo.v17.i4.103629

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (498)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

249

Figures (1-1)

Tables (1-4)

Sum=406

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=60

Apr 15, 2025 (publication date) through Apr 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103629
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103629

Table 1 Characteristics of patients with oesophagus cancer by insurance type and out-of-pocket ratio, mean ± SD/n (%)

Variables	All (n = 2543)	By insurance type			By out-of-pocket ratio
Variables	All (n = 2543)	URBMI (n = 1871)	UEBMI (n = 672)	P value	≤ 60% (n = 1450)	> 60% (n = 1093)	P value
Age	65.46 ± 8.57	65.50 ± 8.21	65.36 ± 9.50	0.703	65.50 ± 9.07	65.41 ± 7.86	0.787
Sex				< 0.001			< 0.001
Male	2088 (82.11)	1465 (78.30)	623 (92.71)		1246 (85.93)	842 (77.04)
Female	455 (17.89)	406 (21.70)	49 (7.29)		204 (14.07)	251 (22.96)
Marriage				0.245			0.498
Married	2381 (93.63)	1745 (93.27)	636 (94.64)		1353 (93.31)	1028 (94.05)
Others	162 (6.37)	126 (6.73)	36 (5.36)		97 (6.69)	65 (5.95)
Nation				1.000			1.000
Han	2519 (99.06)	1853 (99.04)	666 (99.11)		1436 (99.03)	1083 (99.09)
Other minority	24 (0.94)	18 (0.96)	6 (0.89)		14 (0.97)	10 (0.91)
BMI				< 0.001			0.003
18.5-23.9	1550 (60.95)	1181 (63.12)	369 (54.91)		856 (59.03)	694 (63.49)
≥ 24	594 (23.36)	424 (22.66)	170 (25.30)		336 (23.17)	258 (23.60)
< 18.5	399 (15.69)	266 (14.22)	133 (19.79)		258 (17.79)	141 (12.90)
KPS	83.68 ± 8.10	83.90 ± 7.74	83.06 ± 9.02	0.020	82.94 ± 8.44	84.66 ± 7.53	< 0.001
Base disease				< 0.001			< 0.001
No	2033 (79.94)	1567 (83.75)	466 (69.35)		1109 (76.48)	924 (84.54)
Yes	510 (20.06)	304 (16.25)	206 (30.65)		341 (23.52)	169 (15.46)
Pathological				0.297			0.365
Squamous cell carcinoma	2453 (96.46)	1800 (96.21)	653 (97.17)		1394 (96.14)	1059 (96.89)
Others	90 (3.54)	71 (3.79)	19 (2.83)		56 (3.86)	34 (3.11)
TNM				< 0.001			< 0.001
I	196 (7.71)	156 (8.34)	40 (5.95)		66 (4.55)	130 (11.89)
II	634 (24.93)	492 (26.30)	142 (21.13)		324 (22.34)	310 (28.36)
III	989 (38.89)	734 (39.23)	255 (37.95)		584 (40.28)	405 (37.05)
IV	724 (28.47)	489 (26.14)	235 (34.97)		476 (32.83)	248 (22.69)
Radiotherapy				< 0.001			< 0.001
No	1554 (61.11)	1214 (64.89)	340 (50.60)		627 (43.24)	927 (84.81)
Yes	989 (38.89)	657 (35.11)	332 (49.40)		823 (56.76)	166 (15.19)
Chemotherapy				0.002			< 0.001
No	1488 (58.51)	1129 (60.34)	359 (53.42)		712 (49.10)	776 (71.00)
Yes	1055 (41.49)	742 (39.66)	313 (46.58)		738 (50.90)	317 (29.00)
Surgery				0.732			< 0.001
No	1365 (53.68)	1000 (53.45)	365 (54.32)		852 (58.76)	513 (46.94)
Yes	1178 (46.32)	871 (46.55)	307 (45.68)		598 (41.24)	580 (53.06)
Immunotherapy				0.000			0.027
No	2332 (91.70)	1740 (93.00)	592 (88.10)		1314 (90.62)	1018 (93.14)
Yes	211 (8.30)	131 (7.00)	80 (11.90)		136 (9.38)	75 (6.86)
Targeted				< 0.001			< 0.001
No	2450 (96.34)	1827 (97.65)	623 (92.71)		1372 (94.62)	1078 (98.63)
Yes	93 (3.66)	44 (2.35)	49 (7.29)		78 (5.38)	15 (1.37)
FIB				< 0.001			0.006
≤ 3.66	1635 (64.29)	1265 (67.61)	370 (55.06)		899 (62.00)	736 (67.34)
> 3.66	908 (35.71)	606 (32.39)	302 (44.94)		551 (38.00)	357 (32.66)
β2 microglobulin				0.000			0.032
≤ 3.62	2246 (88.32)	1679 (89.74)	567 (84.38)		1263 (87.10)	983 (89.94)
> 3.62	297 (11.68)	192 (10.26)	105 (15.62)		187 (12.90)	110 (10.06)
LDH				0.260			0.280
≤ 236.4	2228 (87.61)	1648 (88.08)	580 (86.31)		1261 (86.97)	967 (88.47)
> 236.4	315 (12.39)	223 (11.92)	92 (13.69)		189 (13.03)	126 (11.53)
PLR				0.022			0.024
≤ 222.22	2082 (81.87)	1552 (82.95)	530 (78.87)		1165 (80.34)	917 (83.90)
> 222.22	461 (18.13)	319 (17.05)	142 (21.13)		285 (19.66)	176 (16.10)
LMR				< 0.001			< 0.001
≤ 3.18	1181 (46.44)	812 (43.40)	369 (54.91)		718 (49.52)	463 (42.36)
> 3.18	1362 (53.56)	1059 (56.60)	303 (45.09)		732 (50.48)	630 (57.64)
NLR				< 0.001			< 0.001
≤ 5.28	2178 (85.65)	1647 (88.03)	531 (79.02)		1201 (82.83)	977 (89.39)
> 5.28	365 (14.35)	224 (11.97)	141 (20.98)		249 (17.17)	116 (10.61)
ALB/GLB				0.006			0.171
≤ 1.08	436 (17.15)	297 (15.87)	139 (20.68)		262 (18.07)	174 (15.92)
> 1.08	2107 (82.85)	1574 (84.13)	533 (79.32)		1188 (81.93)	919 (84.08)
CD4/CD8				0.394			< 0.001
≤ 1.78	1484 (58.36)	1082 (57.83)	402 (59.82)		899 (62.00)	585 (53.52)
> 1.78	1059 (41.64)	789 (42.17)	270 (40.18)		551 (38.00)	508 (46.48)

URBMI: Urban and rural resident basic medical insurance; UEBMI: Urban employee basic medical insurance; BMI: Body mass index; KPS: Karnofsky performance status; TNM: Tumor-node-metastasis; FIB: Fibrinogen; LDH: Lactate dehydrogenase; PLR: Platelet-lymphocyte ratio; LMR: Lymphocyte-monocyte ratio; NLR: Neutrophil-lymphocyte ratio; ALB: Albumin; GLB: Globulin; CD: Cluster of differentiation.

Citation: Wu XL, Li XS, Cheng JH, Deng LX, Hu ZH, Qi J, Lei HK. Oesophageal cancer-specific mortality risk and public health insurance: Prospective cohort study from China. World J Gastrointest Oncol 2025; 17(4): 103629
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103629.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103629